Castle Biosciences (CSTL) – Investment Analysts’ Recent Ratings Updates

Share on StockTwits

Castle Biosciences (NASDAQ: CSTL) has recently received a number of price target changes and ratings updates:

  • 9/4/2019 – Castle Biosciences had its price target raised by analysts at Robert W. Baird from $27.00 to $31.00. They now have an “outperform” rating on the stock.
  • 9/4/2019 – Castle Biosciences was given a new $33.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 9/4/2019 – Castle Biosciences had its price target raised by analysts at BTIG Research to $32.00. They now have a “buy” rating on the stock.
  • 9/4/2019 – Castle Biosciences had its price target raised by analysts at Canaccord Genuity from $26.00 to $34.00. They now have a “buy” rating on the stock.
  • 8/19/2019 – Castle Biosciences is now covered by analysts at Svb Leerink Llc. They set an “outperform” rating and a $28.00 price target on the stock.
  • 8/19/2019 – Castle Biosciences is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $28.00 price target on the stock.
  • 8/19/2019 – Castle Biosciences is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $27.00 price target on the stock.
  • 8/19/2019 – Castle Biosciences is now covered by analysts at BTIG Research. They set a “buy” rating and a $25.00 price target on the stock.
  • 8/19/2019 – Castle Biosciences is now covered by analysts at Canaccord Genuity. They set a “buy” rating and a $26.00 price target on the stock.

NASDAQ:CSTL traded up $0.45 during trading hours on Thursday, hitting $22.94. 178,900 shares of the stock traded hands, compared to its average volume of 140,644. Castle Biosciences has a 1 year low of $17.11 and a 1 year high of $28.50. The firm has a 50 day moving average of $22.77.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Tuesday, September 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.54). The business had revenue of $10.74 million for the quarter, compared to analyst estimates of $7.06 million. As a group, research analysts expect that Castle Biosciences will post -1.57 EPS for the current year.

In other news, major shareholder Mgc Venture Partners 2013 Gp, purchased 312,500 shares of the stock in a transaction on Monday, July 29th. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director David S. Kabakoff purchased 62,500 shares of the stock in a transaction on Monday, July 29th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Featured Article: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.